Intradialytic Pedalling Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population

The purpose of this pilot study is to evaluate 1) the effect of intradialytic pedaling exercise on arterial stiffness and other arterial hemodynamic parameters over 4 months, and 2) the longer-term effect of pedaling on arterial stiffness and other arterial hemodynamic parameters 4 months after finishing the exercise intervention (8 months after study initiation).

The investigators also aim to examine the impact of intradialytic pedaling exercise on general health, anthropometric measures, physical function, and routine laboratory blood markers as secondary outcome measures, as well as to assess feasibility, safety and adverse events associated with the intradialytic pedalling exercise.

Recruitment of more participants in the future will be considered if warranted.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults with end-stage renal disease (stage 5 CKD), who were on a stable in-center hemodialysis regimen (approximately 4 hours 3 times per week) for ≥ 12 weeks prior to recruitment
  • A cardiac evaluation was required within the last year to ensure adequate cardiac function

Exclusion Criteria:

  • Any physical or psychological disability that would impact study participation, such as severe cerebrovascular disease (e.g., hemiparesis, cerebellar ataxia, etc.) or dementia
  • Serum intact parathyroid hormone(iPTH)>250 pmol/L within 30 days prior to screening visit
  • Dysrhythmia or severe cardiac disease, such as congestive heart failure (CHF) Class III-IV, or unstable cardiovascular disease within 90 days prior to recruitment
  • Severe peripheral arterial disease
  • Severe hyperkalemia (>6.5 milliequivalent/L) consistently the last 2 weeks
  • Current active cancer (excluding basal cell carcinoma of the skin)
  • Poorly controlled hypertension (post-dialytic systolic blood pressure ≥ 160mmHg or diastolic blood pressure≥ 100 mmHg) within 4 weeks prior to recruitment
  • Anticipated living donor kidney transplant or any other planned major surgery over the study duration
  • History of poor treatment adherence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Exercise
Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
NO_INTERVENTION: Usual care
Participants receive their usual dialysis for the duration of 4 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in non-invasive measures of arterial stiffness using applanation tonometry.
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in gait speed using a 6 meter walk course and timer.
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in grip strength using a hand dynamometer.
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Safety and adverse events.
Time Frame: 8 months
8 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in peripheral and central blood pressure using a oscillometric cuff-based approach.
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in total cholesterol levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in triglyceride levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in high density lipoprotein cholesterol levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in low-density lipoprotein cholesterol levels
Time Frame: 4 months and 8 months after study initiation
Calculated using the Friedewald equation based on total cholesterol and high density lipoprotein cholesterol levels
4 months and 8 months after study initiation
Change in hemoglobin levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in leukocyte levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in platelet levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in albumin levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in serum electrolyte levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in phosphate levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation
Change in ferritin levels
Time Frame: 4 months and 8 months after study initiation
4 months and 8 months after study initiation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stella S Daskalopoulou, MD, PhD, McGill University Health Centre/Research Institute of the McGill University Health Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (ACTUAL)

November 1, 2015

Study Completion (ACTUAL)

January 1, 2017

Study Registration Dates

First Submitted

January 17, 2017

First Submitted That Met QC Criteria

January 19, 2017

First Posted (ESTIMATE)

January 23, 2017

Study Record Updates

Last Update Posted (ACTUAL)

March 21, 2018

Last Update Submitted That Met QC Criteria

March 20, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease Requiring Chronic Dialysis

Clinical Trials on Exercise

3
Subscribe